Who are Tamoxifen (Nolvadex)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orserdu, Nextstellis, Cerianna, Duavee, Duavee, Osphena.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tamoxifen-nolvadex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tamoxifen (Nolvadex) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tamoxifen (Nolvadex) (Tamoxifen (Nolvadex)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM). Area: Oncology.

phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tamoxifen (Nolvadex) (Tamoxifen (Nolvadex)) — AstraZeneca. Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's action on breast cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tamoxifen (Nolvadex) TARGET	Tamoxifen (Nolvadex)	AstraZeneca	phase 3	Selective estrogen receptor modulator (SERM)	Estrogen receptor
Orserdu	ELACESTRANT	Stemline Therap	marketed	Estrogen Receptor Antagonist [EPC]	Estrogen receptor	2023-01-01
Nextstellis	ESTETROL	Mayne Pharma	marketed	Estrogen	Estrogen receptor	2021-01-01
Cerianna	FLUOROESTRADIOL F-18	GE HealthCare	marketed	Radioactive Diagnostic Agent [EPC]	Estrogen receptor	2020-01-01
Duavee	conjugated-estrogens-bazedoxifene	Pfizer	marketed	Estrogen [EPC]	estrogen receptors α and β	2013-01-01
Duavee	BAZEDOXIFENE	Wyeth Pharms Pfizer	marketed	Estrogen [EPC]	estrogen receptors (ER) α and β	2013-01-01
Osphena	OSPEMIFENE	Duchesnay	marketed	Estrogen Agonist/Antagonist [EPC]	Estrogen receptor beta	2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-03-10 — Duavee · 7683051 · US

Sponsor landscape (Selective estrogen receptor modulator (SERM) class)

University Hospital, Basel, Switzerland · 2 drugs in this class
AstraZeneca · 2 drugs in this class
Estetra · 1 drug in this class
Fundació Privada Eugin · 1 drug in this class
H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Samsung Medical Center · 1 drug in this class
Shandong Suncadia Medicine Co., Ltd. · 1 drug in this class
Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tamoxifen (Nolvadex) — Competitive Intelligence Brief. https://druglandscape.com/ci/tamoxifen-nolvadex. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab